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The NF-E2-related factor-2 (Nrf2) is a transcription factor which regulates the major cellular defense systems and thereby
contributestothepreventionofmanydiseasesincludingcancer.Seleniumdeﬁciencyisassociatedwithahighercancerriskmaking
also this essential trace element a promising candidate for cancer prevention. Two selenoproteins, thioredoxin reductase-1 (TrxR1)
and glutathione peroxidase-2 (GPx2), are targets for Nrf2. Selenium deﬁciency activates Nrf2 as does a TrxR1 knockout making
a synergism between both systems plausible. Although this might hold true for healthy cells, the interplay may turn into the
opposite in cancer cells. The induction of the detoxifying and antioxidant enzymes by Nrf2 will make cancer cells chemoresistant
and will protect them against oxidative damage. The essential role of TrxR1 in maintaining proliferation makes its upregulation
in cancer cells detrimental. The anti-inﬂammatory potential of GPx2 will help to inhibit cancer initiation and inﬂammation-
triggered promotion, but its growth supporting potential will also support tumor growth. This paper considers beneﬁcial and
adverse consequences of the activation of Nrf2 and the selenoproteins which appear to depend on the cancer stage.
1.Introduction
An adequate-to-high selenium supply and activation of Nrf2
by dietary compounds are considered to substantially help
to prevent cancer development. Selenium exerts its eﬀects
mainly as part of selenoproteins with redox functions, and
Nrf2 upregulates enzymes of the adaptive response. Thus,
both systems are involved in the equipment of cells with
a network of enzymes which are supposed to counteract
the transformation of healthy into cancer cells by oxida-
tive damage. However, not all attempts to prevent cancer
by respective dietary supplementation/intervention ended
up with a beneﬁcial outcome; even harmful eﬀects were
observed.
The so-called Linxian trial was among the ﬁrst large ran-
domized, double-blind, primary prevention studies investi-
gating a putative prevention of cancer by vitamins and trace
elements. A mixture of selenium, vitamin E, and β-carotene,
called factor D, signiﬁcantly reduced total mortality, total
cancer mortality, and most signiﬁcantly mortality from
gastric cancer [1]. Although selenium was not given as
a single component, according to subsequent studies it
appeared to have the most eﬃcient eﬀects [2–4]. 10 years
after completion of the Linxian trial, reduction in mortality
remained 5% for total and 11% for gastric cancer [5].
Considering age, the eﬀect of factor D was much stronger
in individuals younger than 55 but almost absent in subjects
older than55 years. The eﬀecton esophageal cancerwas even
reversed by age [5]. The ﬁndings may indicate that selenium
supplementation is only helpful to rescue a marginal deﬁ-
ciency and that a beneﬁt of the supplementation depends
on the stage of carcinogenesis. Whereas selenium appears
to prevent initiation of cancer in healthy cells at young age,
in the elderly it may be harmful and rather support tumor
growth of already initiated cells [5].
Nrf2 as regulator of the endogenous response system has
generallybeenconsideredasbeneﬁcial,too.Sincetwoseleno-
proteins, thioredoxin reductase-1 (TrxR1) and glutathione
peroxidase-2 (GPx2), are induced by Nrf2, a synergism of
bothsystemshasbeenproposed[6].Whereasthismighthold2 International Journal of Cell Biology
true for healthy cells, solely beneﬁcial functions of Nrf2 have
been questioned especially in cancer. Recent data revealed a
“dark” side of Nrf2. Its upregulation in cancer cells provides
an advantage for these cells to grow and, in addition, makes
them resistant against chemotherapy (reviewed in [7, 8]).
Thus, also a beneﬁt of Nrf2 activation might depend on the
cancer stage. Evidence to support this idea is summarized
in view of the mutual regulation of selenium/selenoproteins
and Nrf2 (see Figure 1).
2. Nrf2
Nrf2 is a transcription factor which is kept in the cytosol
by Keap1. Keap1 acts as substrate adaptor for the Cul3-
Rbx1 E3 ligase which ubiquitylates Nrf2 for proteasomal
degradation.Dissociationofthiscomplexisachievedbythiol
modiﬁcation of Keap1 preventing degradation and allowing
newlysynthesizedNrf2totranslocateintothenucleus.There
it binds to the antioxidant/electrophile responsive element
(ARE/EpRE) in the promoter region of its target genes.
The mechanism of activation is complex but has become
relatively clear in the very recent years and is described in
multiple reviews [9–18].
Nrf2 regulates the expression of proteins that collectively
favour cell survival. These comprise enzymes that directly
or indirectly have antioxidant functions, are molecular
chaperones and proteins that enhance glutathione syn-
thesis and regeneration, belong to enzymes of the phase
2 detoxiﬁcation drug metabolism systems, and recognize,
repair, and remove damaged proteins and DNA. Also
proteins that regulate the expression of other transcription
factors, growth factors, and receptors and inhibit cytokine-
mediated inﬂammation and autophagy are targets of Nrf2
(reviewed in [9, 19]). The realm of Nrf2 activators com-
prises endogenous signaling molecules produced during
normal oxygen metabolism and under inﬂammation or
other stress situations. Among activators are H2O2,R O O H ,
ONOO−, oxoaldehydes, and ketones, or cyclopentenones,
like 15-deoxy-Δ12,14-prostaglandin J2.E x o g e n o u sa c t i v a t o r s
comprise dietary isothiocyanates, thiocarbamates, trivalent
arsenicals, quinones, dithiolethiones, vicinal dimercaptanes,
certainstatins,andheavymetals[9,12,19].Activationbythe
later group allows the conclusion that these compounds may
act via initiation of a moderate oxidative/electrophilic stress.
T h ep r o t e c t i v er o l eo fN r f 2i sa l s od e m o n s t r a t e db y
genetic ablation. Nrf2-deﬁcient mice are more susceptible to
carcinogen-induced cancers [20]a n dd e v e l o pm o r es e v e r e
intestinal inﬂammation and a higher number of aberrant
crypts than controls upon dextran sulfate sodium treatment
[21–23]. These ﬁndings indicate a role of Nrf2 in the
prevention of carcinogenesis, especially if inﬂammation
triggered.Incontrast,withoutchallenge,Nrf2-deﬁcientmice
did not show an obvious phenotype [24]. The Nrf2 system,
thus, appears to be an emergency device that comes into play
if a stress is severe enough that it can no longer be handled
by constitutively active systems. An enhanced Nrf2 activity
bymoderatestressmakescellsresistanttoasubsequentmore













Figure 1: Interplay between Nrf2 and the selenoproteins thiore-
doxin reductase-1 (TrxR1) and glutathione peroxidase-2 (GPx2).
(a) In the presence of selenium, the activation of Nrf2 leads to
increased mRNA of both enzymes which can be translated into
respective proteins. (b) Under selenium deﬁciency, Nrf2 is activated
which in principle can lead to an induction of TrxR1 and GPx2
mRNA.Duetolackofselenium,theproteinscannotbesynthesized.
Decrease in TrxR1 further activates Nrf2, which subsequently
upregulates enzymes of the glutathione (GSH) system. These, in
part at least, can compensate the reduced TrxR1 activity. For details
see text.
a vaccination. This way, by upregulation of defense systems,
Nrf2 can prevent cancer initiation by elimination of reactive
oxygen species and detoxiﬁcation of carcinogens.
However, also this coin has two sites, since Nrf2 acti-
vation may not be beneﬁcial under all circumstances. Not
only normal but also tumor cells may beneﬁt from the
protective function of Nrf2 as evidenced by an increase of
Nrf2 and its targets in many cancer cell lines (reviewed
in [7, 17]). The physiological result of the upregulation,
that is, inhibition of apoptosis and autophagy, and increase
of proteasomal degradation of damaged proteins, provides
a superior survival chance also for tumors. Accordingly,
Nrf2 was expressed in a signiﬁcantly higher proportion of
endometrial serous carcinoma, the most aggressive subtype
of endometrial cancer [25]. Nrf2 knockdown inhibited
tumor growth from human cervical carcinoma cells in
xenograftstudies[26]andincreasedeﬃciencyofchemother-
apy in mice bearing subcutaneous tumors of these cells.
In an urethane-induced lung cancer mouse model, Nrf2
deletion decreased tumorigenesis and facilitated death of
early initiated cells by apoptosis [27]. These ﬁndings support
cell survival properties of Nrf2 also in cancer cells.
A constitutive activity of Nrf2 is often reached by muta-
tions in Keap1 and Nrf2 genes themselves [28]. Somatic mu-
tations and loss of heterozygosity of Keap1 were ﬁrst found
in small cell lung carcinoma cell lines [29] and in non-small-
celllungcancers[30]associatedwithanupregulationofNrf2
and respective target genes. RNAi-mediated downregulation
of Nrf2 in these cells suppressed tumor growth in xenograft
experiments and increased sensitivity to chemotherapy [31].
Somatic Keap1 mutations have also been found in cancers of
gallbladderandhepaticbileduct[32]andprostate[33].Nrf2
missense mutations were identiﬁed in lung cancers [34]a n d
in squamous cell carcinomas of oesophagus and skin [35].
The mutations lie in the Nrf2-Keap1 interaction area, whichInternational Journal of Cell Biology 3
might similarly disturb the Nrf2/Keap1 complex formation
as do mutations in the same areas of Keap1 [28].
A Keap1-independent increase in the basal Nrf2 level by
oncogenic alleles of Kras, Braf,a n dcMyc has been described
recently [36]. Whereas an ectopic transduction of mouse
embryonic ﬁbroblasts (MEFs) and NIH3T3 ﬁbroblasts with
K-RasG12D led to an increase in the production of reactive
oxygen species (ROS), inducible expression of endogenous
K-RasG12D inMEFsdecreasedROSproductionandincreased
Nrf2 as well as enzymes of the Nrf2 antioxidant program.
The K-RasG12D mutation is commonly found in human
pancreatic cancer [36]. Accordingly, higher NQO1 protein
and lower levels of ROS biomarkers were detected in murine
and human pancreatic intraepithelial neoplasia (PanIN)
compared to normal tissue. The relevance of oncogene-
mediated Nrf2 activation was proven in PanIN from Nrf2-
deﬁcientmiceinwhichK-RasG12D-inducedproliferationand
tumorigenesis was much less than in PanIN from wild-type
(WT) mice.
A relatively novel system regulated by Nrf2 is the pro-
teasome, a protease complex responsible for the degradation
of proteins tagged with polyubiquitin chains [37]. The 26S
proteasome consists of the catalytic 20S core subunit and the
19S regulatory particle, both consisting of diﬀerent subunits.
The 20S proteasome degrades oxidatively modiﬁed proteins
and is activated upon mild oxidative stress [38]. The S5a
subunitofthe19Sproteasomeandtheα-5subunitofthe20S
proteasome were enhanced in colon tumors compared to the
surrounding normal tissue [39]. The higher levels correlated
with an elevated nuclear localization of Nrf2. Activation
of Nrf2 by electrophilic stress in human colon cancer cell
lines further elevated these subunits and increased TRAIL-
mediated NFκB activation leading to a protection against
apoptosis [39].
Also upregulation of enzymes metabolizing xenobiotics
will not always improve detoxiﬁcation but increase the
toxicity of xenobiotics as reviewed by Hayes et al. [40].
In fact, activated Nrf2 and upregulation of GSTP1 in
hepatocarcinogenesis were the ﬁrst hint to a supportive role
of Nrf2 in cancer cells [41]. Thus, enhancement of Nrf2 and
the resulting upregulation of multidrug resistance-associated
proteins can help cancer cells to escape from chemotherapy
[42, 43]. Chemoresistance has indeed been observed after
treatment of breast cancer cells with tamoxifen [44]a n d
of ovarian cancer cells with cisplatin [45] or other drugs
[46]. Accordingly, knockdown of Nrf2 prevented resistance
to tamoxifen in breast cancer cells [44] and resistance to
d o x o r u b i c i ni nM E F sf r o mN r f 2k n o c k - o u t( K O )m i c e[ 47].
However, Nrf2 is not activated in all types of cancer
cells. It is even decreased in a high number of breast cancer
cellscomparedto normalmammary epithelial celllines. This
coincides with variable but detectable levels of Keap1 and
consistently increased mRNA and protein levels of Cul3, the
ubiquitin ligase tagging Nrf2 for proteasomal degradation.
Accordingly, downregulation of Cul3 in MCF-7 cells rescued
Nrf2 and its targets [48]. A decrease of Nrf2 in the human
breast cancer cells lines MDA-MB-231 and Hs578T is
caused by silencing of the Keap1 RNA-destabilizing miR200a
(miRNA) leading to a higher degradation of Nrf2 [49].
Taken together, cancer cells use all facets of the adaptive
response to escape elimination. In consequence, under
certain circumstances, the protective functions of Nrf2 can
switchtoprocarcinogenicones[7,17,28].Nrf2appearstobe
moreactiveinsomecancercellsandlessinothers,depending
on the cell context, the nature of stress, and the cancer
stage. Also Nrf2 targets may have dual roles in cancer which
will here be discussed for the selenoproteins thioredoxin
reductase-1 (TrxR1) [50, 51] and glutathione peroxidase-2
(GPx2) [52, 53].
3.TrxR1
Thioredoxin reductases (TrxRs) are a family of NADPH-
dependent selenoﬂavoproteins (TrxR1, TrxR2, and TGR)
present in almost all living cells (for reviews see [54, 55]).
Together with thioredoxin (Trx) and NADPH, they build up
the thioredoxin system. The system maintains a reducing
environment in the cytosol, among others required for the
redox regulation of gene expression via transcription factor
activity. It, thus, is involved in DNA repair, angiogenesis,
andinhibitionofapoptosis.Moreover,duringDNAsynthesis
Trx directly transduces electrons to ribonucleotide reductase
which requires the continuous reduction of thereby oxidized
Trx by TrxR. These functions underscore the pivotal role of
TrxR in cell proliferation and survival [55, 56]. Due to its
antioxidant function and its upregulation in cancer cell lines
[57] and human gastrointestinal cancer tissue [58], TrxR was
ﬁrst expected to counteract malignant transformation. This
hypothesis was supported by the fact that TrxR1 regulates
the correct maturation of the tumor suppressor p53 [59, 60].
Furthermore, TrxR1 was the ﬁrst selenoprotein identiﬁed as
target of Nrf2 [50, 61] which at ﬁrst glance was interpreted
as support for a protective role [50, 62]. This might indeed
hold true for the prevention of initiation of carcinogenesis in
healthy cells.
However, it soon turned out that the beneﬁcial eﬀects of
theTrx/TrxRsystemchangetoitsoppositeduringthegrowth
and progression phase of tumors. In fact, upregulation in
cancer cells might also reﬂect the need of the enzyme
for essential functions in cancer cells, the TrxR-dependent
synthesis of deoxyribonucleotides [63]. Downregulation of
TrxR1 by antisense RNA did not increase but inhibited
growth of human hepatocarcinoma cells [64]. Also a knock-
down of TrxR1 in lung carcinoma cells reversed their tu-
morigenicity and invasive potential in a xenograft model
[65]. As underlying mechanism, the decreased expression
of DNA polymerase α was supposed [66]. Alternatively,
the antiapoptotic function of TrxR1 may come into play.
ReducedTrxisrequiredtoinhibitapoptosissignal-regulating
kinase (ASK) [67]. Lack of TrxR1 will prevent inhibition of
ASK making the elimination of malignant cells by apoptosis
possible. Not surprisingly, TrxRs have been suggested as
potentialtargetsforanticancerdrugs[68,69].Theinhibitory
mechanism of such drugs often is the same as used for the
dissociation of Nrf2 from Keap1, namely, thiol modiﬁcation.
Modiﬁcation of the selenol in the active centre of TrxR1
indeed leads to an inhibition of the enzyme activity. On the4 International Journal of Cell Biology
other hand, the same drugs activate Nrf2 as evident from the
upregulation of Nrf2 targets such as glutathione reductase,
a glutathione peroxidase, and GST [69]. The thereby also
upregulated TrxR1 might interfere with the inhibition of
enzyme activity and facilitate cancer cell growth. This should
be considered when selecting drugs to inhibit TrxR activity.
However, TrxR1 is not the only enzyme required for pro-
liferation. Cells from mice with a diﬀerentiated hepatocyte-
speciﬁc KO of TrxR1 were able to proliferate [70]. Prolif-
eration of hepatocytes lacking TrxR1 was observed by in
vivo staining [71] and MEFs from conditioned TrxR1 KO
mouse embryos did not show impaired proliferation [72].
Thus, TrxR1 deletion appears to be compensated by another
system. This most probably is the glutathione (GSH) system
as demonstrated by a severely reduced replicative index if
also GSH is depleted [71], and by an upregulation of GSH
metabolizing enzymes in MEFs from conditioned TrxR1
KO mice [72]. The latter obviously is achieved in TrxR1-
depleted cells by an activation of Nrf2 [73]. Deletion of
TrxR1 in all parenchymal hepatocytes of mice resulted in a
compensatory upregulation of Nrf2 targets including GSTs,
GPx2, and sulﬁredoxin [73]. It was, thus, concluded that
ablation of txnrd1 encoding TrxR1 would mimic oxidative
challenge and switch on a constitutively active Nrf2 pathway
[73]. What is activating Nrf2 when TrxR1 is absent is
unclear, but it ﬁts with the observations made with TrxR1
inhibitors (see above) and the upregulation of Nrf2 targets in
moderateseleniumdeﬁciencyinmice[74,75].Achallenging
hypothesis would be that the thioredoxin system maintains
critical thiol groups in Keap1 in the reduced state and,
thereby, prevents Nrf2 release. That Trx is able to reduce
Cys151 in Keap1 has recently indeed been shown [76]. This
wayTrxR1wouldserve asturn-oﬀsignal forthe Nrf2system.
In sum, a critical balance between Nrf2 and TrxR1
activities might exist which appears worth to be further
investigated.
4.GPx2
The gastrointestinal glutathione peroxidase (GPx2) was ﬁrst
detected in the gastrointestinal system [77]. There it obvi-
ously plays a role in proliferating cells since its concentration
is highest at crypt bases where proliferation takes place [78].
During human colon carcinogenesis, GPx2 is transiently
increased with the highest expression in early adenoma and
decreasing amounts in late stages of malignancy [78, 79]. It
is also upregulated during the neoplastic transformation of
squamous epithelial cells [80] and in lung adenocarcinomas
ofsmokers[81]indicatingthatitsexpressionisnotrestricted
to the gastrointestinal system, but rather characteristic for
rapidly dividing epithelial cells in general [82]. Evidences
for a protective role are provided by genetically modiﬁed
animals. A GPx2 KO rendered mice more susceptible to
skin cancer development upon γ-irradiation [83]. Mice in
whichbothGPx1andGPx2hadbeenknockedoutdeveloped
ileocolitis [84] and later intestinal cancer [85]. The lack
of GPx2 was more detrimental, since one intact allele of
GPx2 (but not of GPx1) was suﬃcient to prevent intestinal
inﬂammation [82]. Mechanistic studies with HT29 cells with
a stable downregulation of GPx2 by siRNA revealed that
GPx2 suppresses COX2 expression and PGE2 production
[86]. Furthermore, the siGPx2 cells exhibited an enhanced
invasive potential and migrated faster in a wound healing
assay [87]. Both eﬀects obviously required the upregulated
COX2 activity since celecoxib, a speciﬁc COX2 inhibitor,
rescued the eﬀects to the level observed in control cells.
A protective role of GPx2 can also be inferred from its
induction by Nrf2 [52]. Thus, the majority of the ﬁndings
described so far characterize GPx2 as an anti-inﬂammatory
enzyme.
The function of GPx2 as an anticarcinogenic enzyme is
lessclear,andevidenceforanadditionalprocarcinogenicrole
is increasing. Apoptosis at colonic crypt bases is drastically
increased in GPx2 KO mice [88]. Inhibition of apoptosis
may reﬂect the physiological function of GPx2 in crypt
bases where it appears to support cell proliferation in the
self-renewal of the intestinal mucosa. Cancer cells, however,
will proﬁt from not being eliminated by apoptosis which
might well be the reason why the siGPx2 cells were not
able to grow anchorage-independently and developed into
much smaller tumors than WT cells when injected into nude
mice [87]. Indeed, GPx2 expression is higher in proliferating
cancer stem cells compared to their diﬀerentiated progeny
[89]. Transcriptional regulation further points into a pro-
carcinogenic direction. GPx2 is induced by ΔNp63 [90], a
transcription factor necessary for cell proliferation, and its
overexpression inhibited oxidant-mediated apoptosis [90].
Activation of the GPx2 promoter by β-catenin [91], which
is the key mediator in the Wnt pathway and constitutively
active in most of intestinal cancers, can again be interpreted
controversially, either as an attempt to counteract carcino-
genesis or to sustain cancer cell growth.
Some tentative answers may be derived from a study
using an inﬂammation triggered model of colon carcino-
genesis, the azoxymethane (AOM)/dextransulfate sodium
(DSS) mouse model. In this study AOM/DSS treatment was
combined with feeding WT and GPx2 KO mice a moderately
Se-deﬁcient, Se-adequate, and Se-supranutritional diet [92].
All AOM/DSS-treated mice developed colitis which was
g e n e r a l l ym o r es e v e r ei nG P x 2K Om i c et h a ni nW Tm i c e
under all Se states and especially high in moderate Se-
deﬁciency. Inﬂammation and accordingly tumor formation
were decreased under the Se supranutritional diet. Tumor
numbers per animal tended to be higher in GPx2 KO mice
at all selenium diets and were decreased by supranutritional
selenium. In contrast, tumor size was smaller in GPx2
KO mice at the moderate selenium deﬁciency and in the
supranutritional status, which correlates with the smaller
tumors in nude mice developing from HT29 cells in
which GPx2 was knocked down (see above). In the same
experiment the eﬀect of sulforaphane (SFN), a well-known
Nrf2 activator, was tested. Surprisingly, it enhanced colitis
in Se-poor WT and GPx2 KO mice but decreased it in
Se-adequate mice to an identical score in both genotypes.
The same dependency on selenium was observed for the
reduction in the number of tumors and apoptotic cells
by SFN in both GPx2 KO and WT mice. This indicatesInternational Journal of Cell Biology 5
that SFN needs a selenoprotein or a selenium-dependent
process to act beneﬁcially. However, this protein cannot
possibly be GPx2 since SFN eﬀects were the same in WT
and GPx2 KO mice. The responsible selenoprotein might
rather be GPx1 which is upregulated in the intestine of
GPx2 KO mice [88], but can only be synthesized when
selenium is available. Taken together, there is an interplay
between selenium and Nrf2 activators, but this appears to
be much more complex than a synergistic upregulation
by Nrf2-mediated transcriptional activation and subsequent
translation of a speciﬁc selenoprotein.
I ns h o r t ,G P x 2a p p e a r st ob eap r o t e c t i v ee n z y m ew i t h
pronounced anti-inﬂammatory potential and antiapoptotic
capacity. Consequences of an upregulated GPx2 might,
however, diﬀer between healthy and malignant tissue. In
healthy tissue, GPx2 is required to maintain the normal self-
renewing of the gastrointestinal epithelium and, as part of
the adaptive response, to depress inﬂammatory processes.
This way GPx2 can inhibit initiation of carcinogenesis.
B u to n c eac e l lh a sb e e np r o g r a m m e dt op r o l i f e r a t ei na n
uncontrolled way, GPx2, inter alia by inhibiting apoptosis,
supports further growth, which does not appear particularly
beneﬁcial. This view is in line with the clinical study
described in the beginning which revealed a decrease of
esophageal cancer incidence by selenium only in younger
but not in older participants [5]. Similarly, in recent N-
nitrosomethylbenzylamine-induced esophageal squamous
cell carcinoma (ESCC) study, the numbers of dysplasia and
ESCC were signiﬁcantly lower in rats on supplementation
with selenium and vitamin E only during the early stage of
tumordevelopmentorduringtheentireexperimentalperiod
but not during the late stage [93].
5. Conclusions
The beneﬁt of upregulation/activation of the Nrf2 pathway
of the selenoproteins TrxR1 and GPx2 diﬀers in healthy and
in cancer cells. Via its physiological role in a program main-
taining the cellular redox state and inter alia the endogenous
defense systems and by preventing apoptosis and damage by
a dysregulated redox homeostasis, Nrf2 might contribute to
the prevention of cancer initiation in healthy cells.
The vital function of TrxR1 is explained by its role in the
replication and proliferation of developing healthy cells. The
physiological function of GPx2 appears to support prolifera-
tion of crypt base epithelial cells in the self-renewal of
the gastrointestinal epithelium. Its antiapoptotic and anti-
inﬂammatory properties might help to inhibit the initiation
and promotion of carcinogenesis by proinﬂammatory medi-
ators.
However, if a cell has been transformed into a malignant
cell and the carcinogenic process has started, the cancer
cells will equally proﬁt from the protective roles of TrxR1,
GPx2, and other Nrf2 programs and, accordingly, will grow
unhampered.
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